[ad_1]
TORINO. mewhere the Molinette hospital reactivated a Covid ward with 22 beds in Medicine B. Also yesterday, Dirmei, the Department of Intercompany Emergencies-Infectious Diseases, contacted two accredited private structures, Gradenigo and Cottolengo, requesting availability to reopen two departments of Covid of 20 beds each. The Mauritian opened one about ten days ago. Rivoli hospital, the Covid Hospital of ASL Torino 3, has already installed a Covid room with 10 beds, plus 5 sub-intensive in the emergency room. Today the first positive patients will arrive at the Ophthalmological Hospital of Turin, where the Covid Hospital previously installed in the Ogrs was reborn.
These are the first countermeasures of the hospital system, dealing with the rising epidemic curve. Yesterday there were no deaths but 336 new infections, 50 more than on Wednesday: 219 asymptomatic, 7 imported. Of the 336 cases, 86 were identified by screening, 18 refer to RSA, 53 to school. More than 7 thousand 7,468, the swabs made.
A rebound that fortunately, at least for now, does not find a counterpart on the hospitalization front: 16 hospitalizations in intensive care (+1 compared to yesterday), 311 not in intensive care (+14). The pressure is still manageable, in recent days the Region has asked ASL executives to guarantee ordinary health activities and continue with the recovery of services frozen during the shutdown.
Even so, there is a strong concern among doctors that the transfer of the infection from the youngest to the oldest groups of the population will end up having an increasingly massive impact on hospitalizations: the average age of the patients, another indication, traveling in the 40-50s.
It is not the only concern. Another, in the therapeutic field, refers to the shortage, in Piedmont as in the rest of Italy, of Remdesivir, the only antiviral drug that to date has demonstrated its efficacy in the treatment of advanced-stage infection. We continue with the stocks granted in recent months by the manufacturer for experimental use. To give an idea, to date there are no more than 100 doses available for the whole of Piedmont, capable of treating about thirty patients. The limited availability in the international market, where the United States has bought the drug, weighs heavily. Serious problem faced by Aifa, the National Medicines Agency, in charge of distribution to the Regions.
